Predict your next investment

Venture Capital
bbbiotechventures.com

See what CB Insights has to offer

Investments

50

Portfolio Exits

14

Funds

3

About BB Biotech Ventures

BB Biotech Ventures is a Guernsey based healthcare venture capital firm focusing on investments in growth capital or earlier-stage technology platform companies. Its primary areas of investment include biotechnology, pharmaceutical, and medical device companies.

BB Biotech Ventures Headquarter Location

c/o Bellevue Asset Management AG Seestrasse 16, Postfach

Kusnacht, 8700,

Switzerland

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest BB Biotech Ventures News

Atlas Genetics在D系列融资中筹集3500万美元

Sep 11, 2020

Atlas Genetics在D系列融资中筹集3500万美元 本文共517个字,阅读需2分钟 Atlas Genetics Ltd., a Bath, England, UK-based ultra-rapid Point-Of-Care molecular diagnostics company, closed $35m in Series D financing.Backers included existing investors Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation – JJDC, Inc., LSP, BB Biotech Ventures, RMI Partners and Technology Venture Partners and new investor Wondfo Biotech, a Chinese in vitro diagnostic company.The company intends to use the funds to finance the clinical trials and commercial launch of a second test for detection of both Chlamydia and Gonorrhoea, planned for regulatory approvals in the US around the end of 2017, further develop additional diagnostics menu, and to expand cartridge manufacturing capacity at Bespak, its cartridge manufacturing partner.Led by Dr John Clarkson, Chief Executive Officer, Atlas Genetics develops ultra-rapid POC diagnostic tests for infectious diseases. Its io® system is a novel molecular diagnostic platform for the ultra-rapid diagnosis of a broad range of infectious diseases based on a patent-protected electrochemical sensor technology. An integrated cartridge, which contains all reagents, is designed to receive an unprocessed clinical specimen. Each cartridge can detect up to 24 different genetic targets from a patient sample.The company also has a commercial office in Boston, MA.FinSMEs23/01/2017 Atlas Genetics Ltd.,一家总部位于英格兰巴斯的超快速护理点分子诊断公司,完成了3500万美元的D系列融资。投资方包括现有投资者诺华风险基金,康索医疗有限公司,强生创新-JJDC,Inc.,LSP,BB Biotech Ventures,RMI Partners and Technology Venture Partners,以及新投资者中国体外诊断公司Wondfo Biotech。该公司打算用这笔资金资助第二项检测衣原体和淋病的试验的临床试验和商业启动,该试验计划于2017年底左右在美国获得监管批准,进一步开发额外的诊断菜单,并扩大其药筒制造合作伙伴Bespak的药筒制造能力。在首席执行官John Clarkson博士的领导下,Atlas Genetics开发了针对传染病的超快速POC诊断测试。其IO®系统是一种新颖的分子诊断平台,基于受专利保护的电化学传感器技术,可对广泛的传染病进行超快速诊断。一个包含所有试剂的集成药筒被设计用于接收未处理的临床标本。每个盒可以从一个病人样本中检测多达24个不同的遗传靶点。该公司还在马萨诸塞州波士顿设有商业办事处。FINSMES23/01/2017 以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

BB Biotech Ventures Investments

50 Investments

BB Biotech Ventures has made 50 investments. Their latest investment was in Natural Dental Implants as part of their Unattributed - III on July 7, 2020.

CBI Logo

BB Biotech Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/20/2020

Unattributed - III

Natural Dental Implants

$1.14M

Yes

1

2/1/2018

Series G

Moderna Therapeutics

$500M

Yes

17

10/4/2017

Series D

Aleva Neurotherapeutics

$13M

No

1

1/23/2017

Series D

Subscribe to see more

$99M

Subscribe to see more

10

12/6/2016

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/20/2020

2/1/2018

10/4/2017

1/23/2017

12/6/2016

Round

Unattributed - III

Series G

Series D

Series D

Series B

Company

Natural Dental Implants

Moderna Therapeutics

Aleva Neurotherapeutics

Subscribe to see more

Subscribe to see more

Amount

$1.14M

$500M

$13M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

17

1

10

10

BB Biotech Ventures Portfolio Exits

14 Portfolio Exits

BB Biotech Ventures has 14 portfolio exits. Their latest portfolio exit was Moderna Therapeutics on December 07, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/7/2018

IPO

$99M

4

12/5/2014

IPO

$99M

2

11/3/2014

IPO

1

6/6/2014

IPO

Subscribe to see more

$99M

Subscribe to see more

10

4/26/2013

Acquired

Subscribe to see more

Subscribe to see more

10

Date

12/7/2018

12/5/2014

11/3/2014

6/6/2014

4/26/2013

Exit

IPO

IPO

IPO

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

2

1

10

10

BB Biotech Ventures Fund History

3 Fund Histories

BB Biotech Ventures has 3 funds, including BB Biotech Ventures III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/29/2009

BB Biotech Ventures III

Multi-Stage Venture Capital

Closed

$96.27M

1

12/31/2005

BB Biotech Ventures II

Subscribe to see more

Subscribe to see more

$99M

10

12/31/1997

BB Bioventures I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

6/29/2009

12/31/2005

12/31/1997

Fund

BB Biotech Ventures III

BB Biotech Ventures II

BB Bioventures I

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Amount

$96.27M

$99M

$99M

Sources

1

10

10

BB Biotech Ventures Team

3 Team Members

BB Biotech Ventures has 3 team members, including current Chief Executive Officer, President, Jacques Bienaimãƒâ©.

Name

Work History

Title

Status

Jacques Bienaimãƒâ©

Chief Executive Officer, President

Current

Martin Munchbach

Pureos Bioventures, and Bellevue Asset Management

Managing Partner

Current

Martin Münchbach

Managing Director

Current

Name

Jacques Bienaimãƒâ©

Martin Munchbach

Martin Münchbach

Work History

Pureos Bioventures, and Bellevue Asset Management

Title

Chief Executive Officer, President

Managing Partner

Managing Director

Status

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.